Formation of LTB4 by fMLP-stimulated alveolar macrophages accounts for eosinophil migration in vitro.
Guinea pig alveolar macrophages obtained by bronchoalveolar lavage were isolated by adherence for 2 h and stimulated with 1 microM of N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP) for different time intervals. The supernatants then were tested for their chemotactic effect on guinea pig peritoneal normodense eosinophils and for release of thromboxane B2, leukotriene B4 (LTB4), and platelet activating factor (PAF). The supernatant from fMLP-stimulated alveolar macrophages induced a significant eosinophil attraction (96.0 +/- 11.9, number of migrating eosinophils [mean +/- SEM], n = 17) as compared to unstimulated macrophages (4.8 +/- 1.4, n = 15). This effect was not accounted for by fMLP carry-over to the macrophages because, in contrast to human eosinophils, fMLP has no chemotactic effect on guinea pig eosinophils. Pretreatment of eosinophils with BN 52021 (100 microM), a specific PAF antagonist, and with indomethacin (10 microM), a cyclooxygenase inhibitor, failed to inhibit migration of eosinophils induced by supernatants from either stimulated or unstimulated alveolar macrophages. In contrast, inhibition of the 5-lipoxygenase enzyme with N-(3-phenoxycinamyl)-acetohydroxamic acid (1 microM) suppressed eosinophil migration by alveolar macrophage supernatants (94.1 +/- 2.6% of inhibition, n = 6). Desensitization of eosinophils by and to LTB4 (10 nM) inhibited migration induced by supernatants from stimulated alveolar macrophages (87.5 +/- 5.4% of desensitization toward LTB4 and 83.1 +/- 5.4% of desensitization toward supernatants, n = 5). Under the present experimental conditions, LTB4 is the only agent implicated in eosinophil migration induced by supernatants from fMLP-stimulated alveolar macrophages.
Hidi
R
R
Unité de Pharmacologie Cellulaire, Unité Associée Institut Pasteur, Paris, France.
Coëffier
E
E
Vargaftig
B B
BB
D000818:Animals; D044482:Benzeneacetamides; D002465:Cell Movement / Q000187:drug effects / Q000502:physiology; D002631:Chemotactic Factors, Eosinophil / Q000378:metabolism*; D004224:Diterpenes; D004804:Eosinophils / Q000187:drug effects / Q000502:physiology*; D046934:Ginkgolides; D006168:Guinea Pigs; D006877:Hydroxamic Acids / Q000494:pharmacology; D007213:Indomethacin / Q000494:pharmacology; D007783:Lactones / Q000494:pharmacology; D007975:Leukotriene B4 / Q000096:biosynthesis* / Q000502:physiology; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology; D016676:Macrophages, Alveolar / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology*; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D012680:Sensitivity and Specificity; D013268:Stimulation, Chemical
D044482:Benzeneacetamides; D002631:Chemotactic Factors, Eosinophil; D004224:Diterpenes; D046934:Ginkgolides; D006877:Hydroxamic Acids; D007783:Lactones; D016859:Lipoxygenase Inhibitors; D010972:Platelet Activating Factor; C056614:N-(3-phenoxycinnamyl)acetohydroxamic acid; D007975:Leukotriene B4; D009240:N-Formylmethionine Leucyl-Phenylalanine; C045856:ginkgolide B; D007213:Indomethacin